Skip to main content
. 2001 Mar 13;98(6):3232–3236. doi: 10.1073/pnas.051624098

Figure 2.

Figure 2

Cancer risk in BRCA2 carriers–survival analysis according to RAD51 genotype. RAD51-135C +-heterozygotes for the 135C polymorphism. RAD51-135wt (wild type) − homozygous normal (GG) at nucleotide 135. (A) Fraction of BRCA2 carriers remaining free of both breast and ovarian cancer. For RAD51-135C heterozygotes, HR = 4.0 [95% confidence interval (CI) 1.6–9.8, P = 0.003]. (B) Fraction of BRCA2 carriers remaining free of breast cancer. For RAD51-135C heterozygotes, HR = 3.46 (95% CI 1.3–9.2, P = 0.01). All BRCA2 carriers who also were RAD51-135C heterozygotes became affected by age 58, whereas 50.4% of those who were RAD51-135 normal homozygotes remained unaffected at the same age. (C) Fraction of BRCA2 carriers remaining free of ovarian cancer. For RAD51-135C heterozygotes, HR = 1.23 (NS).